MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. - Trial NCT05877651
Access comprehensive clinical trial information for NCT05877651 through Pure Global AI's free database. This Phase 1 trial is sponsored by SYZ Cell Therapy Co.. and is currently Completed. The study focuses on Solid Tumors. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
SYZ Cell Therapy Co..
Timeline & Enrollment
Phase 1
Apr 21, 2020
Oct 15, 2021
Primary Outcome
Adverse events and serious adverse events related to MASCT-I
Summary
The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients
 with metastatic or recurrent solid tumors who failed standard therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05877651
Non-Device Trial